Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and enVVeno Medical (NASDAQ:NVNO) Critical Survey

enVVeno Medical (NASDAQ:NVNO) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares enVVeno Medical and Inspira Technologies OXY B.H.N.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-66.39%	-60.42%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Institutional & Insider Ownership

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

enVVeno Medical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for enVVeno Medical and Inspira Technologies OXY B.H.N., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1	1	0	0	1.50
Inspira Technologies OXY B.H.N.	1	0	1	0	2.00

Inspira Technologies OXY B.H.N. has a consensus target price of $2.00, suggesting a potential upside of 406.33%. Given Inspira Technologies OXY B.H.N.’s stronger consensus rating and higher probable upside, analysts plainly believe Inspira Technologies OXY B.H.N. is more favorable than enVVeno Medical.

Valuation and Earnings

This table compares enVVeno Medical and Inspira Technologies OXY B.H.N.”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47 million	($25.54)	-0.38
Inspira Technologies OXY B.H.N.	$290,000.00	48.97	-$13.22 million	N/A	N/A

Inspira Technologies OXY B.H.N. has higher revenue and earnings than enVVeno Medical.

Summary

Inspira Technologies OXY B.H.N. beats enVVeno Medical on 9 of the 10 factors compared between the two stocks.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.